These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21083256)

  • 1. Analytical validation of accelerator mass spectrometry for pharmaceutical development.
    Keck BD; Ognibene T; Vogel JS
    Bioanalysis; 2010 Mar; 2(3):469-85. PubMed ID: 21083256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput liquid chromatography/mass spectrometry method for the quantitation of small molecules using accurate mass technologies in supporting discovery drug screening.
    Ding X; Ghobarah H; Zhang X; Jaochico A; Liu X; Deshmukh G; Liederer BM; Hop CE; Dean B
    Rapid Commun Mass Spectrom; 2013 Feb; 27(3):401-8. PubMed ID: 23280971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry imaging in drug development.
    Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
    Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
    [No Abstract]   [Full Text] [Related]  

  • 4. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures.
    Korfmacher W
    Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491
    [No Abstract]   [Full Text] [Related]  

  • 6. Mass spectrometry imaging for drug distribution studies.
    Prideaux B; Stoeckli M
    J Proteomics; 2012 Aug; 75(16):4999-5013. PubMed ID: 22842290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isotope ratio determination in boron analysis.
    Sah RN; Brown PH
    Biol Trace Elem Res; 1998; 66(1-3):39-53. PubMed ID: 10050906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry.
    Prideaux B; Lenaerts A; Dartois V
    Curr Opin Chem Biol; 2018 Jun; 44():93-100. PubMed ID: 29957376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological accelerator mass spectrometry at Uppsala University.
    Salehpour M; Possnert G; Bryhni H; Palminger-Hallén I; Ståhle L
    Appl Radiat Isot; 2009 Mar; 67(3):495-9. PubMed ID: 18789710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct analysis in real time--high resolution mass spectrometry as a valuable tool for the pharmaceutical drug development.
    Srbek J; Klejdus B; Douša M; Břicháč J; Stasiak P; Reitmajer J; Nováková L
    Talanta; 2014 Dec; 130():518-26. PubMed ID: 25159441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative mass spectrometry imaging of drugs and metabolites: a multiplatform comparison.
    Lamont L; Hadavi D; Viehmann B; Flinders B; Heeren RMA; Vreeken RJ; Porta Siegel T
    Anal Bioanal Chem; 2021 Apr; 413(10):2779-2791. PubMed ID: 33770207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A reflection on fit-for-purpose metabolite investigation at different stages of drug development.
    Leclercq L
    Bioanalysis; 2014 Mar; 6(5):591-4. PubMed ID: 24620799
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer--fitness for purpose in bioanalysis.
    Young GC; Corless S; Felgate CC; Colthup PV
    Rapid Commun Mass Spectrom; 2008 Dec; 22(24):4035-42. PubMed ID: 19009519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-fast quantitative bioanalysis of a pharmaceutical compound using liquid chromatography-tandem mass spectrometry.
    Heinig K; Bucheli F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct; 795(2):337-46. PubMed ID: 14522038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-resolution isotope-dilution mass spectrometry using metabolism of isotope-labeled compounds: application to drug metabolites.
    Vrbanac JJ; Hilgers A; Dubnicka T; Shilliday FB; Humphries D; Hayes RN
    Rapid Commun Mass Spectrom; 2012 Nov; 26(22):2569-76. PubMed ID: 23059872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent development in liquid chromatography/mass spectrometry and emerging technologies for metabolite identification.
    Liang Y; Wang G; Xie L; Sheng L
    Curr Drug Metab; 2011 May; 12(4):329-44. PubMed ID: 21395529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of human mass balance studies with stable isotope-labeled drug and continuous flow-isotope ratio mass spectrometry: a progress report.
    Browne TR; Szabo GK; Ajami A; Browne DG
    J Clin Pharmacol; 1998 Apr; 38(4):309-14. PubMed ID: 9590457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of column-switching liquid chromatography-tandem mass spectrometry for the determination of pharmaceutical compounds in tissue samples.
    Heinig K; Bucheli F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Mar; 769(1):9-26. PubMed ID: 11936699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current developments in LC-MS for pharmaceutical analysis.
    Beccaria M; Cabooter D
    Analyst; 2020 Feb; 145(4):1129-1157. PubMed ID: 31971527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.